Info Business

Good Monday Morning, Its October 31st, 2011, I’m Lynn Lumpkin with CRWENewswire Stocks In Action. CytRx Corporation – symbol CYTR – announced favorable response and safety indications from a group of patients with advanced solid tumors in the Company’s ongoing Phase 1b/2 clinical trial with INNO-206, its tumor-targeting conjugate of the commonly used chemotherapeutic agent doxorubicin. For the…